NO20071160L - Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et farmasoytisk preparat for anvendelse i en fremgangsmate for behandling eller forebygging av androgenmangel - Google Patents
Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et farmasoytisk preparat for anvendelse i en fremgangsmate for behandling eller forebygging av androgenmangelInfo
- Publication number
- NO20071160L NO20071160L NO20071160A NO20071160A NO20071160L NO 20071160 L NO20071160 L NO 20071160L NO 20071160 A NO20071160 A NO 20071160A NO 20071160 A NO20071160 A NO 20071160A NO 20071160 L NO20071160 L NO 20071160L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical composition
- androgen deficiency
- estrogen receptor
- receptor modulator
- selective estrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Abstract
Foreliggende oppfinnelse angår anvendelse av en selektiv østrogenreseptormodulator, eller en isomer, isomerblanding, metabolitt eller et farmasøytisk akseptabelt salt derav for fremstilling av et farmasøytisk preparat for anvendelse i en fremgangsmåte for behandling eller forebygging av androgenmangel eller sykdommer og forstyrrelser forårsaket av androgenmangel hos et mannlig individ.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60690704P | 2004-09-03 | 2004-09-03 | |
FI20041216A FI20041216A0 (fi) | 2004-09-21 | 2004-09-21 | Menetelmä androgeenivajeen hoitoon tai estoon |
PCT/FI2005/000333 WO2006024689A1 (en) | 2004-09-03 | 2005-07-20 | Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20071160L true NO20071160L (no) | 2007-05-25 |
Family
ID=35999733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20071160A NO20071160L (no) | 2004-09-03 | 2007-03-01 | Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et farmasoytisk preparat for anvendelse i en fremgangsmate for behandling eller forebygging av androgenmangel |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1786408A4 (no) |
JP (1) | JP2008511615A (no) |
KR (1) | KR20070059110A (no) |
AU (1) | AU2005279178A1 (no) |
BR (1) | BRPI0514701A (no) |
CA (1) | CA2578852A1 (no) |
MX (1) | MX2007002606A (no) |
NO (1) | NO20071160L (no) |
RU (1) | RU2007112114A (no) |
WO (1) | WO2006024689A1 (no) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101636372B (zh) | 2007-02-14 | 2013-03-27 | 霍尔莫斯医疗有限公司 | 有治疗价值的三苯基丁烯衍生物的制备方法 |
US20080312239A1 (en) * | 2007-06-13 | 2008-12-18 | Quatrx Pharmaceuticals Company | Methods for the treatment of erectile dysfunction using fispemifene |
CN102939287B (zh) | 2010-06-10 | 2016-01-27 | 塞拉根制药公司 | 雌激素受体调节剂及其用途 |
US9193714B2 (en) | 2011-12-14 | 2015-11-24 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
US9744177B2 (en) * | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
EP3240771B1 (en) | 2014-12-29 | 2019-02-20 | OLON S.p.A. | Process for the preparation of ospemifene and fispemifene |
WO2023175010A1 (fr) * | 2022-03-15 | 2023-09-21 | Centre D'etude Des Cellules Souches (Cecs) | Utilisation du bazedoxifene pour augmenter la survie musculaire |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL120262A (en) * | 1996-02-28 | 2001-01-28 | Pfizer | Droloxifene and derivatives thereof for use in increasing serum testosterone levels |
US6632447B1 (en) * | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
TW593256B (en) * | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
CO5271697A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
JP2003534375A (ja) * | 2000-05-26 | 2003-11-18 | フィッチ,ハリー | 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法 |
US7067557B2 (en) * | 2000-05-26 | 2006-06-27 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
EP1666033B1 (en) * | 2001-11-29 | 2008-12-31 | GTX, Inc. | Prevention and treatment of androgen-deprivation induced osteoporosis |
-
2005
- 2005-07-20 CA CA002578852A patent/CA2578852A1/en not_active Abandoned
- 2005-07-20 EP EP05771627A patent/EP1786408A4/en not_active Withdrawn
- 2005-07-20 AU AU2005279178A patent/AU2005279178A1/en not_active Abandoned
- 2005-07-20 KR KR1020077006922A patent/KR20070059110A/ko not_active Application Discontinuation
- 2005-07-20 JP JP2007529372A patent/JP2008511615A/ja not_active Abandoned
- 2005-07-20 WO PCT/FI2005/000333 patent/WO2006024689A1/en active Application Filing
- 2005-07-20 BR BRPI0514701-8A patent/BRPI0514701A/pt not_active IP Right Cessation
- 2005-07-20 RU RU2007112114/15A patent/RU2007112114A/ru not_active Application Discontinuation
- 2005-07-20 MX MX2007002606A patent/MX2007002606A/es unknown
-
2007
- 2007-03-01 NO NO20071160A patent/NO20071160L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2007002606A (es) | 2007-05-15 |
JP2008511615A (ja) | 2008-04-17 |
KR20070059110A (ko) | 2007-06-11 |
AU2005279178A1 (en) | 2006-03-09 |
EP1786408A1 (en) | 2007-05-23 |
BRPI0514701A (pt) | 2008-06-24 |
CA2578852A1 (en) | 2006-03-09 |
EP1786408A4 (en) | 2010-07-28 |
WO2006024689A1 (en) | 2006-03-09 |
RU2007112114A (ru) | 2008-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20073959L (no) | Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller | |
NO20071160L (no) | Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et farmasoytisk preparat for anvendelse i en fremgangsmate for behandling eller forebygging av androgenmangel | |
MA32200B1 (fr) | Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation | |
WO2009068689A3 (en) | Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders | |
NO20072352L (no) | Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet | |
NO20075660L (no) | Blanding for behandling av inflammatoriske sykdommer | |
MX2009001711A (es) | Formulaciones de liberacion sostenida de topiramato. | |
ATE453642T1 (de) | Substituierte phenylaminopyrimidine | |
WO2006015259A3 (en) | Compounds and compositions as modulators of steroid hormone nuclear receptors | |
NO20092584L (no) | Farmasoytiske sammensetninger og deres fremgangsmater for anvendelse | |
DK1933833T3 (da) | Terapi til behandling af overaktiv blære | |
MX2010004494A (es) | Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios. | |
MX2010003550A (es) | Forma de dosificacion intraoral con multiples porciones con propiedades organolepticas. | |
NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
EP2178869A4 (en) | INDOLE COMPOUNDS AS INHIBITORS OF CELL NECROSIS | |
WO2007025005A3 (en) | Sustained release formulations of nalbuphine | |
RS52199B (en) | PHARMACEUTICAL COMPOSITIONS OF THE NEUROACTIVE STEROID AND THEIR USE | |
WO2014170755A3 (en) | Sustained-release formulations of colchicine and methods of using same | |
NO20100301L (no) | Forbedrete brimonidinsammensetninger for behandling av erytem | |
UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
WO2007038506A3 (en) | Method for the treatment of cachexia | |
WO2005077122A3 (en) | Compounds and compositions as lxr modulators | |
NO20083836L (no) | N-hydroksyakrylamidforbindelser | |
NO20080936L (no) | Transdermale medikamentleveringsinnretninger inneholdende O-desmetylvenlafaksin (ODV) eller salter derav | |
NO20082047L (no) | Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |